Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction

Circulation

Volumn 112, Issue 18, 2005, Pages 2812-2820

  Vasilyev, Nikolay ^a   Williams, Timothy ^a   Brennan, Marie Luise ^a   Unzek, Samuel ^a   Zhou, Xiaorong ^a   Heinecke, Jay W ^c   Spitz, Douglas R ^b   Topol, Eric J ^a   Hazen, Stanley L ^a   Pen, Marc S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amino acids; Infarction; Inflammation; Remodeling

Indexed keywords

ACROLEIN; ALDEHYDE; ALPHA AMINO ACID; CYTOTOXIC AGENT; FORMALDEHYDE; GLYCINE; LYSINE; MYELOPEROXIDASE; OXIDIZING AGENT; THREONINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; HEART DILATATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE NECROSIS; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; MASS SPECTROMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY;

ACROLEIN; ALDEHYDES; ANIMALS; AORTA; CATTLE; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; FORMALDEHYDE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; HYDROGEN PEROXIDE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; NEUTROPHILS; PEROXIDASE; PULMONARY ARTERY; VENTRICULAR REMODELING;

EID: 27844442307     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.542340     Document Type: Article

References (40)

1. Gonon AT, Gourine AV, Middelveld RJ, Alving K. Pernow J. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol. 2001;96:454-462.
2. Maekawa Y. Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002;39:241-246.
3. Fisher TC, Meiselmann HJ. Polymorphonuclear leukocytes in ischemic vascular disease. Thromb Res. 1994;74(suppl 1):S21-S34.
4. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000;28:1717-1725.
5. Desrochers PE, Mookhtiar K. Van Wart HE, Hasty KA, Weiss SJ. Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem. 1992;267:5005-5012.
6. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix, metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279-41287.
7. Stief TW, Martin E, Caso F, Rodriguez JM. Oxidation susceptibility of plasminogen activator inhibitors of human plasma. Thromb Res. 1990;60:177-180.
8. Askari A, Brennan ML, zhou X, Drinko J, morehead A, Thomas JT, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-624.
9. Babior BM. Oxygen-dependent microbial killing by phagocytes (second of two parts). N Engl J Med. 1978;198:721-725.
10. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
11. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest. 1996;98:1283-1289.
12. Hurst JK, Albrich JM, Green TR, Rosen H, Klebanoff S. Myeloperoxidase-dependent fluorescein chlorination by stimulated neutrophils. J Biol Chem. 1984;259:4812-4821.
13. Zgliczynski JM, Stelmaszynska T, Ostrowiski W, Naskalski J, Sznajd J. Myeloperoxidase of human leukaemic leucocytes: oxidation of amino acids in the presence of hydrogen peroxide. Eur J Biochem. 1968;4:540-547.
14. Zgliczynski JM, Stelmaszynska T, Domanski J, Ostrowski W. Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase. Biochim Biophys Acta. 1971;235:419-424.
15. Hazen SL, Hsu FF, d'Avignon A, Heinecke JW. Human neutrophils employ myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry. 1998;37:6864-6873.
16. Hazen SL, d'Avignon A, Anderson MM, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to oxidize alpha-amino acids to a family of reactive aldehydes: mechanistic studies identifying labile intermediates along the reaction pathway. J Biol Chem. 1998;273:4997-5005.
17. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein: a mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest. 1997;99:424-432.
18. Hazen SL, Hsu FF, Heinecke JW. p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes: a chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem. 1996;271:1861-1867.
19. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
20. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004;24:1143-1146.
21. Wu W, Chen Y, Hazen SL. Eosinophil peroxidase nitrates protein tyrosyl residues: implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem. 1999;274:25933-25944.
22. Nelson DP, Kiesow LA. Enthalpy of decomposition of hydrogen peroxide by catalase at 25 degrees C (with molar extinction coefficients of H2O2 solutions in the UV). Anal Biochem. 1972;49:474-478.
23. Morris JC. The acid ionization constant of HOCl from 5-35°C. J Phys Chem. 1966;70:3798-3805.
24. Hazen SL, Gaul JP, Hsu FF, Crowley JR, d'Avignon A, Heinecke JW. p-Hydroxyphenytacetatdehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues. J Biol Chem. 1997;272:16990-16998.
25. Spitz DR, Malcolm RR, Roberts RJ. Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in H2O2-resistant cell lines: do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochem J. 1990;267:453-459.
26. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, Lusis AJ. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest. 2001;107:419-430.
27. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
28. Hsu FF, Hazen SL, Giblin D, Turk J, Heinecke JW, Gross ML. Mass spectrometry and ion processes. Int J Mass Spectrom. 1999;185/186/187:795-812.
29. Freidig A, Hofhuis M, Van HI, Hermens J. Glutathione depletion in rat hepatocytes: a mixture toxicity study with alpha, beta-unsaturated esters. Xenobiotica. 2001;31:295-307.
30. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int. 2001;39:141-149.
31. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003;92:136-140.
32. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10 substudy. Circulation. 2000;102:2329-2334.
33. Schauenstein E, Esterbauer H, Zollner H. Aldehydes in Biological Systems. London, UK: Pion Limited; 1977.
34. Spitz DR, Sullivan SJ, Malcolm RR, Roberts RJ. Glutathione dependent metabolism and detoxification of 4-hydroxy-2-nonenal. Free Radic Biol Med. 1991;11:415-423.
35. Ishikawa T, Esterbauer H, Sies H. Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J Biol Chem. 1986;261:1576-1581.
36. Jensson H, Guthenberg C, Alin P, Mannervik B. Rat glutathione transferase 8-8, an enzyme efficiently detoxifying 4-hydroxyalk-2-enals. FEBS Lett. 1986;203:207-209.
37. Linder M. Nutritional Biochemistry and Metabolism. New York, NY: Elsevier Science Publishing Co Inc: 1992.
38. Mertz W, ed. Trace Elements in Human and Animal Nutrition. New York, NY: Academic Press; 1986:426-430.
39. Hoffmeyer MR, Jones SP, Ross CR, Sharp B, Grisham MB, Laroux FS. Stalker TJ, Scalia R, Lefer DJ. Myocardial ischemia/reperfusion injury in NADPH oxidase-deficient mice. Circ Res. 2000;87:812-817.
40. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV. Double-blind, randomized trial of an anti-CD 18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) study. Circulation. 2001;104:2778-2783.